Kimura Y, Hamamoto K, Suzuki K, Yokoyama K, Hisada K, Kasagi K, Konishi J, Ichiya Y, Masuda K, Kubo A
Department of Radiology, Ehime University School of Medicine.
Kaku Igaku. 1995 Mar;32(3):311-21.
The phase II clinical trial of a strontium (89Sr) chloride agent (SMS. 2P) was performed in 9 patients with painful bone metastases secondary to prostate cancer. After an intravenous administration, 89Sr circulated in the plasma and was rapidly cleared. Urinary excretion varied widely among the patients. No serious acute side effects were observed. A mild transient increase in pain was reported by 4 patients 2-4 days after administration, two of whom complained of mild nausea or vomiting. All symptoms improved and never became a clinical problem. There were some abnormal hematological parameters. In particular, a decrease in the platelet level seemed to be a marrow suppression due to 89Sr irradiation. It is difficult to discriminate between the effects of 89Sr and the progress of the disease using tumor markers. The pain level improved within 2 weeks after administration and the effect continued for at least 8 weeks, which improved the quality of life for these patients.
对9例前列腺癌继发骨转移疼痛患者进行了氯化锶（89Sr）制剂（SMS. 2P）的II期临床试验。静脉给药后，89Sr在血浆中循环并迅速清除。患者间尿排泄差异很大。未观察到严重急性副作用。4例患者在给药后2 - 4天报告疼痛有轻度短暂增加，其中2例抱怨有轻度恶心或呕吐。所有症状均改善，未成为临床问题。有一些血液学参数异常。特别是血小板水平降低似乎是89Sr照射引起的骨髓抑制。使用肿瘤标志物难以区分89Sr的作用和疾病进展。给药后2周内疼痛水平改善，且效果持续至少8周，改善了这些患者的生活质量。
